CN107613998A - 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品 - Google Patents
作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品 Download PDFInfo
- Publication number
- CN107613998A CN107613998A CN201680030796.2A CN201680030796A CN107613998A CN 107613998 A CN107613998 A CN 107613998A CN 201680030796 A CN201680030796 A CN 201680030796A CN 107613998 A CN107613998 A CN 107613998A
- Authority
- CN
- China
- Prior art keywords
- water extract
- pleurotus ferulae
- prevention
- active ingredient
- metabolic disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 80
- 235000006521 Pleurotus eryngii var ferulae Nutrition 0.000 title claims abstract description 75
- 244000088486 Pleurotus eryngii var. ferulae Species 0.000 title claims abstract description 75
- 239000000284 extract Substances 0.000 title claims abstract description 71
- 239000004480 active ingredient Substances 0.000 title claims abstract description 24
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 22
- 235000001497 healthy food Nutrition 0.000 title claims abstract description 18
- 230000002265 prevention Effects 0.000 title claims abstract description 17
- 208000016097 disease of metabolism Diseases 0.000 title claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 23
- 235000013361 beverage Nutrition 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- -1 compound vitamin Chemical class 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 235000013305 food Nutrition 0.000 abstract description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 15
- 239000008103 glucose Substances 0.000 abstract description 15
- 238000004519 manufacturing process Methods 0.000 description 23
- 235000009200 high fat diet Nutrition 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 238000010171 animal model Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 210000000577 adipose tissue Anatomy 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 230000037213 diet Effects 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- 208000008589 Obesity Diseases 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000021110 pickles Nutrition 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 229960004425 sibutramine Drugs 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001512 FEMA 4601 Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 235000001681 Pleurotus eryngii Nutrition 0.000 description 2
- 244000252132 Pleurotus eryngii Species 0.000 description 2
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012407 engineering method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003044 randomized block design Methods 0.000 description 2
- 235000019203 rebaudioside A Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 241000510609 Ferula Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- MGJLSBDCWOSMHL-WFMNFSIZSA-N Ononin Natural products O(C)c1ccc(C=2C(=O)c3c(OC=2)cc(O[C@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc3)cc1 MGJLSBDCWOSMHL-WFMNFSIZSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000318836 Pleurotus nebrodensis Species 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- MGJLSBDCWOSMHL-MIUGBVLSSA-N ononin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-MIUGBVLSSA-N 0.000 description 1
- MGJLSBDCWOSMHL-UHFFFAOYSA-N ononoside Natural products C1=CC(OC)=CC=C1C1=COC2=CC(OC3C(C(O)C(O)C(CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
本发明涉及作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用组合物,证实了阿魏菇水提取物对摄取高脂肪食物时发生的脂肪蓄积和血糖增加具有抑制作用,从而具有能够将其用作预防或治疗肥胖或糖尿病的药物组合物或健康功能性食品的优异效果。
Description
技术领域
本发明涉及作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用组合物或健康功能性食品,更详细而言,涉及作为有效成分含有阿魏菇水提取物的预防或治疗肥胖和糖尿病等代谢性疾病的药物组合物或健康功能性食品,上述阿魏菇水提取物对摄取高脂肪食物时发生的脂肪蓄积和血糖增加具有抑制作用。
背景技术
近年来,生活水平随着经济的发展而提高,所以能够享受丰富的饮食生活,但是以肉食为主的饮食变化等导致摄取过多热量。这种现代人的饮食的变化由于严重缺乏运动等导致消耗的热量少,因此呈现出肥胖人口快速增加的趋势。据报告,肥胖不仅导致外型问题,而且由于持续肥胖,引起各种疾病,如高血压、糖尿病、高血脂症、冠状动脉疾病等成人疾病,还引起乳腺癌、子宫癌和结肠癌等,目前肥胖被认为是致命性疾病中的一种[J.Biol.Chem.,273,32487~32490(1998);Nature,404,652~660(2000)]。
代谢性疾病是糖质、脂质、蛋白质、维生素、矿物质和水分等失衡引起的疾病的总称,其中,与脂质相关的代谢性疾病是指生物体内过度蓄积脂质而引发的疾病,具体而言,有肥胖、糖尿病等。
肥胖是由能量的摄取和消耗失衡所导致的,多余的能量转换为脂肪细胞的形态而储存在体内。更详细地,人体内约有200亿个脂肪细胞,其在哺乳类的生物体内起到蓄积或放出能量的作用,脂肪细胞将消耗后剩余的能量以中性脂肪形态储存,之后,能量枯竭时再将其分解为游离脂肪酸和葡萄糖。当这种储存和分解过程失衡导致过度地蓄积能量时,脂肪细胞的数量或大小增加,从而发生肥胖。
糖尿病分为胰岛素依赖型糖尿病(1型糖尿病)、非胰岛素依赖型糖尿病(2型糖尿病)和营养失调性糖尿病(MRDM),据报告,占韩国糖尿病患者的90%以上的2型糖尿病是以高血糖为特征的代谢疾病,是由于遗传性、代谢性、环境因素导致的胰腺β细胞的胰岛素分泌降低或外周组织中的胰岛素抵抗性增加而发生的。
糖尿病与肥胖在发病机制上具有非常密切的关联,与此相关地,因肥胖而身体脂肪增加时,显示出胰岛素敏感性降低的症状,另外,已知对2型糖尿病患者而言,肥胖与胰岛素抵抗性具有密切的相关关系,肥胖越严重,胰岛素抵抗性也越严重。
目前,作为治疗肥胖的治疗剂,可以大致分为通过作用于中枢神经系统来影响食欲的药物以及通过作用于胃肠道来抑制吸收的药物。正在市售的作用于中枢神经系统的药物,按照各个机制,分别有抑制五羟色胺(5HT)神经系统的氟苯丙胺、右芬氟拉明等药物,基于去甲肾上腺素神经系统的麻黄碱和咖啡因等药物,以及最近的同时作用于五羟色胺和去甲肾上腺素神经系统而抑制肥胖的西布曲明(Sibutramine)等药物。此外,作为作用于胃肠道而抑制肥胖的药物,代表性的有最近被许可作为肥胖治疗剂的奥利司他等,奥利司他通过抑制胰腺中生成的脂肪酶来减少脂肪的吸收。
但是,已知以往使用的肥胖治疗剂中的氟苯丙胺等引发原发性肺动脉高血压或心脏瓣膜病变之类的副作用,因此最近被禁止使用,西布曲明具有升高血压的副作用,奥利司他具有引发消化道功能紊乱等的副作用。另外,其他化学合成药物也发生血压降低或乳酸酸血症等问题,因此存在如心力衰竭、肾脏疾病患者无法使用的问题。
因此,目前需要副作用少且预防或治疗肥胖以及与其关系密切的糖尿病的方法,最近,从天然材料中寻找其解决方法的研究正在活跃地进行。
据报告全世界范围内约有1万多种蘑菇类,由于食用和药用价值高,为了确保能够用作微生物有用资源,在欧洲、美国、日本等发达国家正在进行大量研究。报告有多种研究结果,特别是蘑菇类生产的生理活性物质的副作用少,在毒性方面也安全,具有调节人体内免疫系统的功能、抗癌效果、调节新陈代谢等多种功能。
其中,已知在中国和中亚自然生长的阿魏菇是具有疏经通络、止咳、消炎、对胃肠疾病有效的药用植物,在中医学书籍等中介绍了它能够排除人体内的毒素、止咳、消炎,而且对妇科系统疾病也有效,是高功能性蘑菇。
上述阿魏菇的学名为Pleurotus eryngii var.ferulea(Pf:P.ferulea),是杏鲍菇的变种。英文名称为Ferula Oyster Mushroom,如果进行解释,则为阿魏侧耳。在中国称为白灵侧耳。它在中国的干燥地带新疆地区的阿魏树上野生,生长温度为8~20度的中温,适合在韩国的春季、秋季栽培。
作为本发明的现有技术,在韩国授权专利第10-1402193号中公开了含有阿魏菇子实体提取物或阿魏菇菌丝体提取物或阿魏菇菌丝体培养液的抗炎用皮肤外用剂组合物,但是关于将阿魏菇子实体和菌丝体提取物作为有效成分的抗炎用组合物。
另一方面,虽然在韩国公开专利第10-2012-0143701号(分案申请第10-2015-0055605号)中公开了含有阿魏菇的水提取物作为有效成分的高血脂症预防和治疗用组合物,但是本发明的发明人对上述阿魏菇水提取物进行了反复研究,结果证实该提取物对摄取高脂肪食物时发生的脂肪蓄积和血糖增加具有抑制作用的又一效果,从而完成了本发明,然而至今为止上述这些内容未被公开过。
发明内容
发明要解决的问题
因此,本发明的目的是提供一种作为有效成分含有阿魏菇水提取物的预防和治疗肥胖或糖尿病等代谢性疾病的药物组合物。
本发明的另一目的是提供一种作为有效成分含有阿魏菇水提取物的预防和改善肥胖或糖尿病等代谢性疾病的健康功能性食品。
解决问题的技术方案
本发明是通过获取阿魏菇的水提取物,将其作为测试材料来验证抗肥胖或抗糖尿病功能,对此进行评价而完成的。
发明效果
本发明的阿魏菇的水提取物对摄取高脂肪食物时发生的脂肪蓄积和血糖增加具有抑制作用,从而具有能够提供将其作为有效成分而含有的预防和治疗肥胖或糖尿病等代谢性疾病的药物组合物的效果以及能够用作预防和改善肥胖或糖尿病等代谢性疾病的健康功能性食品的效果。
附图说明
图1是表示随阿魏菇水提取物变化的实验动物的体重变化图表。
图2是表示随阿魏菇水提取物变化的实验动物的整体脂肪组织重量变化图表。
图3是表示随阿魏菇水提取物变化的实验动物的脂肪组织的形态学变化图表。
图4示表示随阿魏菇水提取物变化的实验动物的肝组织的脂肪蓄积变化图表。
图5是表示随阿魏菇水提取物变化的实验动物的血糖变化图表。
具体实施方式
本发明的阿魏菇的水提取物是通过以下步骤制得:准备阿魏菇的粉末的步骤;将上述阿魏菇粉末与水进行混合的步骤;以及将上述混合物在20至60℃的温度中提取12至36小时的步骤。
上述阿魏菇的水提取物可以按照通常的植物提取物的制造方法来制得。最优选地,将上述阿魏菇以15℃进行冷温干燥后,进行粉碎,然后除去残渣,在每100mL水中添加0.1至20g的上述粉碎物,最优选地,在每100mL提取溶剂中添加1至5g的粉碎物而进行提取。不优选40℃以上的热风干燥。另外,阿魏菇粉碎物的含量相对于提取溶剂过少的情况下,阿魏菇的胆固醇吸收效果不充分,因此不优选,阿魏菇粉碎物的含量相对于提取溶剂的量过多的情况下,效果并没有因含量增加而显著增强,但是生产成本增多,因此在生产率方面不优选。
阿魏菇的提取条件优选为将阿魏菇与作为提取溶剂的水进行混合后,在20至60℃的温度中提取12至36小时,最优选在30至40℃的温度中提取20至24小时。在20℃以下的低温条件下提取时,为了提取有效提取成分,需要长时间,在60℃以上的高温条件下提取时,由于活性降低,因此不优选。特别是,在100℃中热水提取15分钟以上时水提取物依然失去活性,因此不能使用。另外,当将提取时间缩短至12小时时,提取的有效成分的浓度低,当提取36小时以上的长时间时,尽管提取时间增加,但提取有效成分的浓度增加甚微,因此在生产率方面不优选。另外,优选地,利用滤布等对上述方法提取的阿魏菇的水提取液进行过滤后,离心分离滤液而除去沉淀物,然后进行减压浓缩或浓缩后,进行冻干而使用。
另一方面,根据上述实施方式制备的上述阿魏菇的水提取物可以作为有效成分而被含在预防和治疗肥胖或糖尿病等代谢性疾病的药物组合物中。作为上述预防和治疗肥胖或糖尿病等代谢性疾病的药物组合物中的有效成分的阿魏菇的水提取物的含量优选为0.01至30重量%。作为有效成分的阿魏菇的水提取物的含量小于0.01重量%时,对摄取高脂肪食物时发生的脂肪蓄积和血糖增加的抑制效果甚微,超过30重量%时,尽管含量增加,但抑制活性的效果增加甚微,因此不经济。优选地,组合物中的阿魏菇的水提取物的含量为0.001至50重量%,最优选为0.1至30重量%。
作为有效成分含有这样的阿魏菇的水提取物的药物组合物还可以包含在制备时通常使用的适当的载体、赋形剂和稀释剂。可以被包含在作为有效成分含有本发明的阿魏菇的水提取物的药品中的载体、赋形剂和稀释剂,例如可举出乳糖、葡萄糖、蔗糖、山梨糖醇、甘露糖醇、木糖醇、赤藓糖醇、麦芽糖醇、淀粉、阿拉伯胶、藻酸盐、明胶、磷酸钙、硅酸钙、纤维素、甲基纤维素、微晶纤维素、聚乙烯吡咯烷酮、水、羟基苯甲酸甲酯、羟基苯甲酸丙酯、滑石、硬脂酸镁和矿物油。
本发明的作为有效成分含有阿魏菇的水提取物的药物组合物可以分别根据通常的方法以散剂、片剂、硬质胶囊、软质胶囊、液体制剂等口服剂型来使用。上述口服剂型是表示包括用于口服的固体制剂和液态制剂,用于口服给药的固体制剂可以包含片剂、丸剂、散剂、颗粒剂、胶囊等,这样的固体制剂可以在上述提取物中混合至少一种以上的赋形剂而制得,上述赋形剂例如为淀粉、碳酸钙(calcium carbonate)、蔗糖(sucrose)或乳糖(lactose)、明胶等。另外,除了单纯的赋形剂以外,还可以使用硬脂酸镁、滑石之类的润滑剂。作为用于口服的液态制剂,有悬浮剂、内服液剂、乳剂、糖浆剂等,除了常用的作为单纯稀释剂的水、液体石蜡之外,可以包含各种赋形剂,例如湿润剂、甜味剂、芳香剂、保存剂等。
含有本发明的阿魏菇的水提取物的药物组合物的优选给药量根据状态和体重、疾病的程度、药物形态、给药途径和时间而不同,但是本领域技术人员可以适当选择。优选地,本发明的作为有效成分含有阿魏菇的水提取物的药物以阿魏菇的水提取物的量为基准,以成人标准(60kg体重),可以按1天0.0001至100mg/kg进行给药,为了更加有效,优选按0.01至10mg/kg进行给药。给药次数可以1天给药1次,也可以分数次进行给药。上述给药量和给药次数在任何方面均不限定本发明的范围。
根据本发明的另一实施方式,提供一种作为有效成分含有阿魏菇的水提取物的治疗和改善肥胖或糖尿病等代谢性疾病的健康功能性食品。在本说明书中,“健康功能性食品”是指含有一种或一种以上的营养素的天然物质或加工品,优选地指经过某种程度的加工工序而成为能够直接食用的状态的食品。
作为可以添加本发明的阿魏菇的水提取物的健康功能性食品,例如有各种食品类、饮料、口香糖、茶、维生素复合剂等。进一步地,在本发明中,食品包括特殊营养食品(例如,配方乳类、婴幼儿食品等)、加工肉食品、鱼肉制品、豆腐类、冻类面类(例如,拉面类、面条类等)、健康辅助食品、调味食品(例如,酱油、大酱、辣椒酱、混合酱等)、调料汁、饼干类(例如,点心类)、乳加工品(例如,发酵乳、奶酪等)、其他加工食品、泡菜、腌制食品(各种泡菜类、酱菜等)、饮料(例如,水果饮料、蔬菜类饮料、豆乳类、发酵饮料类等)、天然调味料(例如,拉面汤等),但不限于此。上述食品、饮料或食品添加剂可以用通常的制造方法制造。
本说明书中,功能性食品是指利用物理性、生化性、生物工程方法等对食品赋予附加值使得该食品的功能能够在特定目的上作用、表现的食品组或者设计并加工为能够对生物体充分发挥食品组成所具有的生物体防御节奏调节、与防止疾病及恢复等相关的身体调节功能的食品。上述功能性食品中可以包含在食品学上允许使用的食品辅助添加剂,还可以包含在功能性食品的制造中通常使用的适当的载体、赋形剂和稀释剂。
在本说明书中,饮料是指消除口渴或者享受味道而喝的液体的总称,旨在包括功能性饮料。上述饮料除了按照指示的比率含有既是必要成分也是有效成分的上述阿魏菇的水提取物以外,对其他成分没有特别限定,可以像普通饮料那样含有各种香味剂或天然碳水化合物等作为追加成分。作为上述天然碳水化合物的例子,可以是单糖,例如葡萄糖、果糖等二糖,例如麦芽糖、蔗糖等多糖,例如糊精、环糊精等通常的糖,以及木糖醇、山梨糖醇、赤藓糖醇等糖醇。作为上述以外的香味剂,可以有利地使用天然香味剂(索马甜、甜叶菊提取物(例如莱鲍迪苷A、甘草甜素等)和合成香味剂(糖精、阿斯巴甜等)。相对于每100mL本发明的组合物,上述天然碳水化合物的比率一般为约1至20g,可以优选为5至12g。此外,本发明的组合物可以进一步含有用于制造天然果汁、果汁饮料、蔬菜饮料的果肉。
除上述以外,本发明的健康功能性食品可以含有各种营养剂、维生素、矿物(电解质)、合成风味剂和天然风味剂等风味剂、着色剂和填充剂(奶酪、巧克力等)、果胶酸及其盐、藻酸及其盐、有机酸、保护性胶体增粘剂、pH调节剂、稳定剂、防腐剂、甘油、水、碳酸饮料中使用的碳酸化剂等。这样的成分可以独立使用,或者可以组合使用。这样的添加剂的比率没有那么重要,但是,相对于100重量份本发明的阿魏菇的水提取物,可以在0至20重量份的范围选择。
本说明书中,功能性饮料是指利用物理性、生化性、生物工程方法等对饮料赋予附加价值使得饮料的功能能够在特定目的上作用、表现的饮料组或者设计并加工为能够对生物体充分发挥饮料组成所具有的生物体防御节奏调节、与防止疾病及恢复等相关的身体调节功能的饮料。
上述功能性饮料除了按照指示的比率含有既是必要成分也是有效成分的上述本发明的阿魏菇的水提取物以外,对其他成分没有特别限定,可以像普通饮料那样含有各种香味剂或天然碳水化合物等作为追加成分。作为上述天然碳水化合物的例子,可以是单糖,例如葡萄糖、果糖等二糖,例如麦芽糖、蔗糖等多糖,例如糊精、环糊精等通常的糖,以及木糖醇、山梨糖醇、赤藓糖醇等糖醇。作为上述以外的香味剂,可以有利地使用天然香味剂(索马甜、甜叶菊提取物(例如莱鲍迪苷A、甘草甜素等)和合成香味剂(糖精、阿斯巴甜等)。相对于每100mL本发明的组合物,上述天然碳水化合物的比率一般为约1至20g,可以优选为5至12g。
另外,对于以治疗或改善肥胖或糖尿病等代谢性疾病为目的的健康功能性食品而言,上述提取物的量占全部食品重量的0.01至15重量%,对于饮料组合物而言,比率则如下,以100mL为基准,可以包含0.02至5g,优选包含0.3至1g。
下面,举出实施例详细说明本发明的具体内容。下述实施例只是用于例示本发明,本发明并不限于下述实施例。
实施例1.准备阿魏菇的水提取物
从市场上购买干燥的阿魏菇(Pleurotus eryngii var.ferulea(Pf.),进行粗粉末化后,装入纱布袋中,相对于每1g粉末,作为提取溶剂,混合50mL的水,然后于37℃在振荡培养器中提取24小时。将震荡培养器的上清液以2500rpm离心分离10分钟后,收集过滤后的上清液,用作下述测试材料。
实施例2.阿魏菇的水提取物的抗肥胖和抗糖尿病功效实验
为了证实阿魏菇水提取物的抗肥胖和抗糖尿病功效,利用实验动物测定体重增加量、脂肪组织重量、脂肪和肝组织的形态学变化、血糖含量。
实施例2-1:实验动物和饲料
就实验动物而言,将C57BL/6系8周龄雄性小鼠在浦项工科大学实验动物中心用固体饲料适应1周后,将平均体重为25g的小鼠根据随机区组设计(randomized blockdesign)分成3组,每组6只,饲养8周。将实验组分为正常饲料组(NCD)、高脂肪饲料组(HFD)、一同摄取高脂肪饲料和阿魏菇水提取物(HFD+PEF)的组。正常饲料组供给脂肪占总卡路里的10%的普通饲料,高脂肪饲料组供给脂肪占总卡路里的60%的饲料,一同摄取高脂肪饲料和阿魏菇水提取物的组供给添加有8重量%阿魏菇水提取物的高脂肪饲料,饲养期间,水和饲料可以自由摄取。动物饲养室温度维持22±1℃,照明周期调节为12小时(08;00-20;00),所有动物实验是在浦项工科大学动物实验伦理委员会(Pohang University ofScience and Technology Institutional Animal Care and Use Committee)的承认下遵守动物实验伦理准则而进行的。
实施例2-2:体重测定
每周测定1次实验动物的饲料摄取量和体重。各实验组的体重增加率是在实验期间以1周为间隔在规定时间进行测定的,饲料效率(Food Efficiency Ratio:FER)如下述数学式1所示,将从实验饲料供给日开始至牺牲日为止作为实验期间,实验期间的体重增加量除以实验期间的饲料摄取量而算出。
数学式1
[数学式1]
如图1所示,对8周期间的体重进行确认的结果,证实了喂食高脂肪饲料的组(HFD)与喂食正常饲料的组(NCD)相比,体重急剧增加,而在一同摄取高脂肪饲料和阿魏菇水提取物的组(HFD+PEF)中体重增加显著减少。
另外,如下述表1所示,就饲料效率而言,证实了与正常饲料组(NCD)相比,高脂肪饲料组(HFD)增加大约4.3倍,但是与高脂肪饲料组(HFD)相比,一同摄取高脂肪饲料和阿魏菇水提取物的组(HFD+PEF)的饲料效率减少约1.8倍。
表1
[表1]
因此,证实了摄取阿魏菇的水提取物时,能够显著抑制高脂肪饲料引起的体重增加。
实施例2-3:证实抗肥胖效果
为了证实阿魏菇水提取物的抗肥胖效果,测定了各实验组的脂肪组织的重量,并且利用显微镜观察了脂肪细胞的大小变化。
首先,为了证实阿魏菇水提取物对于脂肪组织的增加的抑制效果,摘出实验动物的整体脂肪组织并测定重量。
如图2所示,正常饲料组(NCD)的整体脂肪组织重量显示为0.47g,高脂肪饲料组(HFD)的整体脂肪组织重量显示出2.3g的高水平,但是一同摄取高脂肪饲料和阿魏菇水提取物的组(HFD+PEF)中为0.67g,证实了整体脂肪组织减少。
然后,为了进行脂肪和肝组织的形态学观察,将实验开始8周后从实验动物摘出的脂肪组织(WAT)和肝(Liver)组织固定在4%低聚甲醛溶液中。固定结束后的各组织用流动的水清洗后,根据依次增加的浓度的顺序用乙醇进行脱水,经过渗透过程,包埋在石蜡中后,制成了4um的组织切片。然后,实施苏木精和伊红(hematotaxyin and eosin)染色后,用光学显微镜进行观察。
如图3所示,用显微镜确认阿魏菇水提取物对脂肪组织(WAT)形态的效果,结果,摄取高脂肪饲料的组(HFD)与摄取正常饲料的组(NCD)相比,脂肪细胞大小显著增加,而在一同摄取高脂肪饲料和阿魏菇水提取物的组(HFD+PEF)中,脂肪细胞的大小显著减小。
另外,如图4所示,用显微镜确认阿魏菇水提取物抑制肝(Liver)组织的脂肪蓄积的效果,结果,与正常饲料组(NCD)相比,在摄取高脂肪饲料的组(HFD)中,脂肪蓄积整体分布,而在一同摄取高脂肪饲料和阿魏菇水提取物的组(HFD+PEF)中,观察到脂肪蓄积接近于摄取正常饲料的组,显著减少。
因此,确认了阿魏菇水提取物对高脂肪饲料导致的脂肪蓄积具有抑制效果。
实施例2-4:证实抗糖尿病效
为了证实阿魏菇水提取物的抗糖尿病效果,从实验动物的血液中分离血浆,测定血糖含量。为此,实验开始8周后,从实验动物采取血液,在4℃以14000rpm离心分离10分钟而获得血浆,使用血糖测定仪(Accu-chekperforma nan,Accu-chek)测定血浆内血糖(glucose)。
如图5所示,血糖测定结果,摄取高脂肪饲料的组(HFD)与正常饲料组(NCD)相比,血糖增加,而一同摄取高脂肪饲料和阿魏菇水提取物的组的血糖(HFD+PEF)减少。
因此,分析的结果为阿魏菇水提取物还对高脂肪饲料导致的血糖增加具有抑制效果。
下面记载了将本发明的阿魏菇的水提取物作为有效成分的各种剂型的例子,但是本发明的制剂不限于此。
制造例1.散剂的制造
阿魏菇水提取物粉末 20mg
乳糖 100mg
滑石 10mg
混合上述成分并填充于密封袋而制造了散剂。
制造例2.片剂的制造
阿魏菇水提取物粉末 10mg
玉米淀粉 100mg
乳糖 100mg
硬脂酸镁 2mg
混合上述成分后,根据通常的片剂的制造方法进行打片而制造了片剂。
制造例3.胶囊的制造
阿魏菇水提取物粉末 10mg
结晶纤维素 3mg
乳糖 14.8mg
硬脂酸镁 0.2mg
根据通常的胶囊制造方法混合上述成分并填充于明胶胶囊而制造了胶囊。
制造例4.液体制剂的制造
阿魏菇水提取物粉末 20mg
异构糖 10g
甘露糖醇 5g
纯化水 适量
根据通常的液体制剂的制造方法,在纯化水中加入各个成分并使其溶解,加入适量的柠檬香后,混合上述成分,然后加入纯化水而调节成加入纯化水后的整体为100mL,然后填充于棕色瓶中,进行灭菌而制造了液体制剂。
制造例5.注射剂的制造
阿魏菇水提取物粉末 10mg
甘露糖醇 180mg
注射用灭菌蒸馏水 3000mg
Na2HPO4,12H2O 25mg
根据通常的注射剂的制造方法按每1安瓿(2mL)包含上述成分含量的方式来制造。
制造例6.健康功能性食品的制造
阿魏菇水提取物粉末 1000mg
维生素混合物 适量
维生素A 乙酸盐 70μg
维生素E 1.0mg
维生素B1 0.13mg
维生素B2 0.15mg
维生素B6 0.5mg
维生素B12 0.2μg
维生素C 10mg
生物素 10μg
烟酰胺 1.7mg
叶酸 50μg
泛酸钙 0.5mg
无机物混合物 适量
硫酸亚铁 1.75mg
氧化锌 0.82mg
碳酸镁 25.3mg
磷酸二氢钾 15mg
磷酸氢钙 55mg
柠檬酸钾 90mg
碳酸钙 100mg
氯化镁 24.8mg
上述的维生素和矿物质混合物的组成比是将比较适合健康食品的成分以优选实施例的方式混合组成的,但是该配比可以任意地变更实施,根据通常的健康食品制造方法混合上述成分后,制造颗粒,可以根据通常的方法用于健康食品组合物的制造。
产业上的利用可能性
如以上说明的那样,本发明证实了阿魏菇水提取物对摄取高脂肪食物时发生的脂肪蓄积和血糖增加具有抑制效果,从而具有能够将其作为预防和治疗肥胖和糖尿病等代谢性疾病的药物组合物或者预防和改善肥胖和糖尿病等代谢性疾病的健康功能性食品来提供的优异效果,这是一个在制药和健康食品产业上有用的发明。
Claims (4)
1.一种代谢性疾病的预防和治疗用药物组合物,其特征在于,作为有效成分含有阿魏菇的水提取物,所述代谢性疾病包括肥胖或糖尿病。
2.根据权利要求1所述的代谢性疾病的预防和治疗用药物组合物,其特征在于,所述药物组合物被制成散剂、片剂、硬质胶囊、软质胶囊、液体制剂和注射剂中的任一种剂型。
3.一种代谢性疾病的预防和改善用健康功能性食品,其特征在于,作为有效成分含有阿魏菇的水提取物,所述代谢性疾病包括肥胖或糖尿病。
4.根据权利要求3所述的代谢性疾病的预防和改善用健康功能性食品,其特征在于,所述健康功能性食品选自食品类、饮料、口香糖、茶和维生素复合剂中的任一种。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0073680 | 2015-05-27 | ||
KR1020150073680A KR20160141027A (ko) | 2015-05-27 | 2015-05-27 | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 |
PCT/KR2016/004806 WO2016190566A2 (ko) | 2015-05-27 | 2016-05-09 | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107613998A true CN107613998A (zh) | 2018-01-19 |
Family
ID=57392567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680030796.2A Pending CN107613998A (zh) | 2015-05-27 | 2016-05-09 | 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180296615A1 (zh) |
JP (1) | JP2018516987A (zh) |
KR (1) | KR20160141027A (zh) |
CN (1) | CN107613998A (zh) |
WO (1) | WO2016190566A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108371267A (zh) * | 2018-03-05 | 2018-08-07 | 乌鲁木齐利多人宇生物科技有限公司 | 一种阿魏菇无花果饮品及其制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102192586B1 (ko) * | 2018-02-12 | 2020-12-18 | (주)노바셀테크놀로지 | 아위버섯의 추출물 또는 분말을 유효성분으로 함유하는 지방간 질환 치료용 약학적 조성물 및 간기능 개선용 건강기능식품 |
KR20190133482A (ko) * | 2018-05-23 | 2019-12-03 | 동국제약 주식회사 | 흰강낭콩 및 아위버섯 추출물을 함유하는 항비만 또는 체지방 감소용 조성물 |
KR102429280B1 (ko) * | 2020-06-29 | 2022-08-05 | (주)노바셀테크놀로지 | 신규 교잡품종 버섯의 분말을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 또는 건강기능성식품 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009029786A (ja) * | 2007-06-22 | 2009-02-12 | Hokuto Corp | 膵リパーゼ阻害剤およびその製造方法と治療方法 |
CN101914168A (zh) * | 2010-09-06 | 2010-12-15 | 石河子大学 | 阿魏侧耳多糖及其组合物的医药用途和制备方法 |
CN102533444A (zh) * | 2011-12-28 | 2012-07-04 | 北京电子科技职业学院 | 一种白灵菇挥发性风味成分提取物及提取方法和鉴定方法 |
CN103275198A (zh) * | 2013-06-13 | 2013-09-04 | 石河子大学 | 一种阿魏菇凝集素分离纯化的方法 |
CN104023734A (zh) * | 2011-12-12 | 2014-09-03 | 庆尚北道 | 含阿魏菇水提取物作为有效成分的用于预防或治疗高脂血症的组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372462B2 (en) * | 1999-10-15 | 2002-04-16 | Medmyco Ltd. | Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms |
KR100543726B1 (ko) * | 2003-11-26 | 2006-01-20 | 차월석 | 아위버섯 추출물을 함유하는 항암효과 상승제 조성물 |
JP2006347960A (ja) * | 2005-06-16 | 2006-12-28 | Yukito Akiyama | 糖類分解酵素阻害活性剤及びこれを含有する健康食品 |
TWI519307B (zh) * | 2007-10-24 | 2016-02-01 | Suntory Holdings Ltd | The ligand of peroxisome proliferator activated receptor (PPAR) |
KR20100088794A (ko) * | 2009-02-02 | 2010-08-11 | 인제대학교 산학협력단 | 새송이버섯 추출물을 유효성분으로 함유하는 제 2형 당뇨병에 의한 지질대사 장애 및 당뇨합병증 질환의 예방 및 치료용 조성물 |
-
2015
- 2015-05-27 KR KR1020150073680A patent/KR20160141027A/ko not_active Application Discontinuation
-
2016
- 2016-05-09 WO PCT/KR2016/004806 patent/WO2016190566A2/ko active Application Filing
- 2016-05-09 CN CN201680030796.2A patent/CN107613998A/zh active Pending
- 2016-05-09 JP JP2018514756A patent/JP2018516987A/ja active Pending
- 2016-05-09 US US15/576,768 patent/US20180296615A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009029786A (ja) * | 2007-06-22 | 2009-02-12 | Hokuto Corp | 膵リパーゼ阻害剤およびその製造方法と治療方法 |
JP2012250989A (ja) * | 2007-06-22 | 2012-12-20 | Hokuto Corp | 膵リパーゼ阻害剤およびその製造方法 |
CN101914168A (zh) * | 2010-09-06 | 2010-12-15 | 石河子大学 | 阿魏侧耳多糖及其组合物的医药用途和制备方法 |
CN104023734A (zh) * | 2011-12-12 | 2014-09-03 | 庆尚北道 | 含阿魏菇水提取物作为有效成分的用于预防或治疗高脂血症的组合物 |
CN102533444A (zh) * | 2011-12-28 | 2012-07-04 | 北京电子科技职业学院 | 一种白灵菇挥发性风味成分提取物及提取方法和鉴定方法 |
CN103275198A (zh) * | 2013-06-13 | 2013-09-04 | 石河子大学 | 一种阿魏菇凝集素分离纯化的方法 |
Non-Patent Citations (5)
Title |
---|
JINNCHYI WANG等: "Antihyperglycemic Activity of Exopolysaccharide Produced by Mushroom Pleurotus ferulae with Submerged Liquid Culture on Streptozotocin-induced Diabetic Rats", 《JOURNAL OF FOOD AND NUTRITION RSEARCH》 * |
NUHU ALAM等: "Antihyperlipidemic activities of Pleurotus ferulae on biochemical and histological function in hypercholesterolemic rats", 《JOURNAL OF RESEARCH IN MEDICAL SCIENCES》 * |
王为兰等: "阿魏菇药理功能的研究进展", 《安徽农业科学》 * |
王斌等: "《白灵菇标准化生产》", 31 December 2011, 河南科学技术出版社 * |
许金国等: "白灵菇多糖及总氮含量的测定", 《食用菌》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108371267A (zh) * | 2018-03-05 | 2018-08-07 | 乌鲁木齐利多人宇生物科技有限公司 | 一种阿魏菇无花果饮品及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2016190566A3 (ko) | 2017-01-19 |
WO2016190566A9 (ko) | 2017-04-13 |
US20180296615A1 (en) | 2018-10-18 |
WO2016190566A2 (ko) | 2016-12-01 |
JP2018516987A (ja) | 2018-06-28 |
KR20160141027A (ko) | 2016-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101144059B1 (ko) | 석류 추출물 및 홍삼 추출물을 포함하는 당뇨병 또는비만의 예방 또는 치료용 조성물 | |
JP2008174539A (ja) | 紫色の馬鈴薯を使用した肥満患者用の健康機能食品 | |
KR20190010506A (ko) | 저분자 유효 사포닌의 함량이 증대되고 벤조피렌은 저감된 돌외잎 추출물의 제조방법 및 이에 따른 돌외잎 추출물 | |
CN107080250A (zh) | 一种辅助降血糖的组合物、饮料及其制备方法 | |
CN108404019A (zh) | 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法 | |
CN107613998A (zh) | 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品 | |
CN106456693A (zh) | 糖尿病预防或改善剂 | |
KR20070000573A (ko) | 혈당저하 및 변비효과가 있는 건강식품 조성물 | |
JPWO2004112817A1 (ja) | セリ科植物由来抽出物およびその製造方法 | |
KR101565964B1 (ko) | 아위버섯의 물 추출물을 유효성분으로 함유하는 고지혈증 예방 또는 치료용 조성물 | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
KR101859166B1 (ko) | 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물 | |
KR20110105627A (ko) | 누에 체액을 함유하는 항비만 조성물 | |
KR102501725B1 (ko) | 칼슘 흡수율을 높인 녹각 및 오미자 유래 칼슘 조성물 및 이의 제조방법 | |
WO2005094858A1 (ja) | 抗糖尿病用組成物 | |
KR101391647B1 (ko) | 항비만 조성물 | |
CN101646428A (zh) | 用于治疗或预防糖尿病的包括来自紫草的紫草素衍生物的药物组合物及其用途 | |
JP3476835B2 (ja) | ヤーコン・ウーロン配合食品 | |
US20070092587A1 (en) | Extract from plant of japanese parsley family and process for producing the same | |
KR20130082249A (ko) | 담쟁이 덩쿨 추출물을 함유하는 대사성 질환 예방 또는 개선용 조성물 | |
AU2006347121B2 (en) | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia | |
JP2003095941A (ja) | 糖質消化酵素阻害剤、血糖値上昇抑制剤、肥満治療予防剤、糖尿病治療予防剤、健康飲食物 | |
KR101166698B1 (ko) | 알파-글루코시데이즈 억제 활성을 갖는 팥 근연종 추출물 | |
KR20170055366A (ko) | 흰민들레 뿌리 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물 | |
KR101391648B1 (ko) | 항비만 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180119 |